Digestive Diseases and Sciences

, Volume 51, Issue 1, pp 168–172 | Cite as

Relapse of Inflammatory Bowel Disease Associated With Use of Nonsteroidal Anti-Inflammatory Drugs

  • Angela M. Meyer
  • Nizar N. Ramzan
  • Russell I. Heigh
  • Jonathan A. Leighton


To determine whether an association exists between relapse in inflammatory bowel disease and use of nonsteroidal anti-inflammatory drugs (NSAIDs), a retrospective records review was conducted of patients with Crohn's disease, ulcerative colitis, or indeterminate colitis examined at an outpatient tertiary care center between July 17, 2000, and November 1, 2001. Extracted data collected during the patient's last visit included medication use, maintenance therapy, disease activity, and smoking status. Use of NSAIDs was defined as a daily dose or more of any type the month before relapse. Of 60 patients (22, relapse; 38, remission), 9 (41%) in relapse and 10 (26%) in remission used NSAIDs. Maintenance therapy varied from 68% (relapse) to 92% (remission). The adjusted odds ratio between medication use and relapse was 6.31 (95% confidence interval, 1.16–34.38; P = .03). Use of NSAIDs was associated with relapse. A prospective cohort study that corrects for maintenance therapy is needed to evaluate this relationship.

Key Words

Crohn's disease colitis ulcerative inflammatory bowel disease nonsteroidal anti-inflammatory drugs 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    1 Wallace JL: Nonsteroidal anti-inflammatory drugs and gastroenteropathy: The second hundred years. Gastroenterology 112:1000–1016, 1997CrossRefPubMedGoogle Scholar
  2. 2.
    2 Rodger IW, Chan C-C: Inducible cyclooxygenase (COX-2): A target for novel anti-inflammatory drugs. In Neuroinflammation, Mechanisms and Management. Wood PL, (ed). Totowa, NJ, Humana Press, 1998, pp 355–373Google Scholar
  3. 3.
    3 Dubois RN, Abramson SB, Crofford L, et al.: Cyclooxygenase in biology and disease. FASEB J 12:1063–1073, 1998PubMedGoogle Scholar
  4. 4.
    4 Rampton DS, Sladen GE: Relapse of ulcerative proctocolitis during treatment with nonsteroidal anti-inflammatory drugs. Postgrad Med J 57:297–299, 1981PubMedGoogle Scholar
  5. 5.
    5 Kaufmann HJ, Taubin HL: Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 107:513–516, 1987PubMedGoogle Scholar
  6. 6.
    6 Hendel J, Nielson OH: Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease. Am J Gastroenterol 92:1170–1173, 1997PubMedGoogle Scholar
  7. 7.
    7 Rampton DS, McNeil NI, Sarner M: Analgesic ingestion and other factors preceding relapse in ulcerative colitis. Gut 24:187–189, 1983PubMedGoogle Scholar
  8. 8.
    8 Davies NM: Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine. Dis Colon Rectum 38:1311–1321, 1995CrossRefPubMedGoogle Scholar
  9. 9.
    9 Pearson DJ, Stones NA, Bentley SJ: Proctocolitis induced by salicylate and associated with asthma and recurrent nasal polyps. Br Med J (Clin Res Ed) 287:1675, 1983Google Scholar
  10. 10.
    10 Walt RP, Hawkey CJ, Langman MJ: Colitis associated with non-steroidal anti-inflammatory drugs (letter). Br Med J (Clin Res Ed) 288:238, 1984Google Scholar
  11. 11.
    11 Rutherford D, Stockdill G, Hamer-Hodges DW, Ferguson A: Proctolitis induced by salicylate. Br Med J (Clin Res Ed) 288:794, 1984Google Scholar
  12. 12.
    12 Evans JM, McMahon AD, Murray FE, McDevitt DG, MacDonald TM: Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut 40:619–622, 1997PubMedGoogle Scholar
  13. 13.
    13 Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G: Effects of nonsteroidal anti-inflammatory drugs on inflammatory bowel disease: A case-control study. Am J Gastroenterol 95:1949–1954, 2000CrossRefPubMedGoogle Scholar
  14. 14.
    14 Smale S, Sigthorsson G, Foster R, Forgacs I, Bjarnason I: NSAIDs and relapse of IBD (abstract). Gastroenterology 122(Suppl 1):A23, 2002Google Scholar
  15. 15.
    15 Bonner GF, Walczak M, Kitchen L, Bayona M: Tolerance of nonsteroidal anti-inflammatory drugs in patients with inflammatory bowel disease. Am J Gastroenterol 95:1946–1948, 2000CrossRefPubMedGoogle Scholar
  16. 16.
    16 Dominitz JA, Koepsell TD, Boyko EJ: Association between analgesic use and inflammatory bowel disease (IBD) flares: A retrospective cohort study (abstract). Gastroenterology 118(Suppl 2):A581, 2000Google Scholar
  17. 17.
    17 Bonner GF, Vennamaneni S: Use of nonsteroidal anti-inflammatory drugs in outpatients with inflammatory bowel disease (abstract). Gastroenterology 2001;120(Suppl 1):A269, 2001Google Scholar
  18. 18.
    18 Bombardier C, Laine L, Reicin A, et al., for the VIGOR Study Group: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343:1520–1528, 2000CrossRefPubMedGoogle Scholar
  19. 19.
    19 Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR: Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Natl Acad Sci U S A 96:7563–7568, 1999PubMedGoogle Scholar
  20. 20.
    20 Wolfe MM, Lichtenstein DR, Singh G: Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 340:1888–1899, 1999CrossRefPubMedGoogle Scholar
  21. 21.
    21 McCartney SA, Mitchell JA, Fairclough PD, Farthing MJ, Warner TD: Selective COX-2 inhibitors and human inflammatory bowel disease. Aliment Pharmacol Ther 13:1115–1117, 1999CrossRefPubMedGoogle Scholar
  22. 22.
    22 Singer II, Kawka DW, Schloemann S, Tessner T, Riehl T, Stenson WF: Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 115:297–306, 1998CrossRefPubMedGoogle Scholar
  23. 23.
    23 Roberts PJ, Morgan K, Miller R, Hunter JO, Middleton SJ: Neuronal COX-2 expression in human myenteric plexus in active inflammatory bowel disease. Gut 48:468–472, 2001CrossRefPubMedGoogle Scholar
  24. 24.
    24 Agoff SN, Brentnall TA, Crispin DA, et al.: The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. Am J Pathol 157:737–745, 2000PubMedGoogle Scholar
  25. 25.
    25 Wallace JL, Reuter BK, McKnight W, Bak A: Selective inhibitors of cyclooxygenase-2: are they really effective, selective, and GI-safe? J Clin Gastroenterol 27(Suppl 1):S28–S34, 1998PubMedGoogle Scholar
  26. 26.
    26 O'Brien J: Nonsteroidal anti-inflammatory drugs in patients with inflammatory bowel disease (editorial). Am J Gastroenterol 95:1859–1861, 2000CrossRefPubMedGoogle Scholar
  27. 27.
    27 Mizuno H, Sakamoto C, Matsuda K, et al.: Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 112:387–397, 1997CrossRefPubMedGoogle Scholar
  28. 28.
    28 Lesch CA, Kraus ER, Sanchez B, Gilbertsen R, Guglietta A: Lack of beneficial effect of COX-2 inhibitors in an experimental model of colitis. Methods Find Exp Clin Pharmacol 21:99–104, 1999CrossRefPubMedGoogle Scholar
  29. 29.
    29 Karmeli F, Cohen P, Rachmilewitz D: Cyclo-oxygenase-2 inhibitors ameliorate the severity of experimental colitis in rats. Eur J Gastroentrol Hepatol 12:223–231, 2000Google Scholar
  30. 30.
    30 Reuter BK, Asfaha S, Buret A, Sharkey KA, Wallace JL: Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest 98:2076–2085, 1996PubMedGoogle Scholar
  31. 31.
    31 Bonner GF: Exacerbation of inflammatory bowel disease associated with use of celecoxib (letter). Am J Gastroenterol 96:1306–1308, 2001CrossRefPubMedGoogle Scholar
  32. 32.
    32 Mahadevan U, Loftus EV Jr., Tremaine WJ, Sandborn WJ: Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol 97:910–914, 2002CrossRefPubMedGoogle Scholar
  33. 33.
    33 Bjarnason I, Hayllar J, MacPherson AJ, Russell AS: Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 104:1832–1847, 1993PubMedGoogle Scholar
  34. 34.
    34 Bjorkman D: Nonsteroidal anti-inflammatory drug-associated toxicity of the liver, lower gastrointestinal tract, and esophagus. Am J Med 105:17S–21S, 1998PubMedGoogle Scholar
  35. 35.
    35 Hanauer SB, Sandborn W, and the Practice Parameters Committee of the American College of Gastroenterology: Management of Crohn's disease in adults. Am J Gastroenterol 96:635–643, 2001CrossRefPubMedGoogle Scholar
  36. 36.
    36 Faucheron JL: Toxicity of non-steroidal anti-inflammatory drugs in the large bowel. Eur J Gastroenterol Hepatol 11:389–392, 1999PubMedGoogle Scholar
  37. 37.
    37 Puspok A, Kiener HP, Oberhuber G: Clinical, endoscopic, and histologic spectrum of nonsteroidal anti-inflammatory drug-induced lesions in the colon. Dis Colon Rectum 43:685–691, 2000PubMedGoogle Scholar
  38. 38.
    38 Reinisch W, Miehsler WP, Dejaco C, Glauninger P, Vogelsang H: Treatment of peripheral arthropathy in IBD with rofecoxib, a selective COX-2 inhibitor (abstract). Gastroenterology 120(Suppl 1):A277, 2001Google Scholar
  39. 39.
    39 Kornbluth A, Sachar DB: Ulcerative colitis practice guidelines in adults. Am J Gastroenterol 92:204–211, 1997PubMedGoogle Scholar
  40. 40.
    40 Tierney LM, McPhee SJ, Papdakis MA: Current Medical Diagnosis and Treatment 2001, 40th ed. New York, Lange Medical Books/McGraw Hill, 2001, pp 641–645Google Scholar

Copyright information

© Springer Science + Business Media, Inc. 2006

Authors and Affiliations

  • Angela M. Meyer
    • 1
  • Nizar N. Ramzan
    • 1
  • Russell I. Heigh
    • 1
  • Jonathan A. Leighton
    • 1
    • 2
  1. 1.Division of Gastroenterology and HepatologyMayo ClinicScottsdaleUSA
  2. 2.Division of Gastroenterology and HepatologyMayo ClinicScottsdale

Personalised recommendations